About This Trial
BCMA-targeted ADC in combination with standard of care for myeloma.
Primary Endpoints
- Progression-free survival
- Overall response rate
Latest Update
February 2026
Primary analysis shows significant PFS improvement. Re-filing with FDA planned for Q2 2026.